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Summary Photodynamic therapy (PDT) of hepatic tumours has been restricted owing to the preferential
retention of photosensitizers in liver tissue. We therefore investigated interstitial tumour illumination as a
means of selective PDT. A piece of colon carcinoma CC531 was implanted in the liver of Wag/Rij rats.
Photofrin was administered (5 mg kg-' i.v.) 2 days before laser illumination. Tumours with a mean (±s.e.)
diameter of 5.7±0.1 mm (n = 106, 20 days after implantation) were illuminated with 625 nm light, at
200 mW cm-' from a 0.5 cm cylindrical diffuser and either 100, 200, 400, 800 or 1600 J cm-'. Control groups
received either laser illumination only, Photofrin only or diffuser insertion only. Short-term effects were studied
on the second day after illumination by light microscopy and computer-assisted integration of the cir-
cumference of damaged areas. Long-term effects were studied on day 36. To determine the biochemistry of
liver damage and function, serum ASAT and ALAT levels were measured on day 1 and 2, and antipyrine
clearance on day 1. Tumour and surrounding liver necrosis increased with light dose delivered (P<0.001).
Best long-term results were obtained at 800 J cm'l with complete tumour remission in 4 out of 6 animals. No
deterioration in liver function was found. The results of this study show the ability of interstitial PDT to cause
major destruction of tumour tissue in the liver combined with minimal liver damage.
The only curative treatment for liver metastases is surgical
resection. However, only 5-10% of patients with hepatic
metastases from colorectal cancer are amenable to this type
of therapy, and the operative mortality and morbidity rates
are relatively high (4-25% and 16-46%, respectively) (Steele
& Ravikumar, 1989; Sugerbaker & Kemeny, 1989; Wagman
et al., 1990). Photodynamic therapy (PDT) is a relatively new
local treatment modality, which has been used successfully in
the treatment of various malignant tumours, including cancer
of the bladder, skin, upper respiratory tract and gastrointes-
tinal tract (Dougherty, 1987; 1989; Manyak et al., 1988;
Gomer, 1989; Wilson et al., 1991). This type of therapy is
based on the accumulation of a photosensitiser in malignant
tissues and the subsequent illumination with light of an
appropriate wavelength, which creates a reactive species that
upon decay to its ground state transforms available oxygen
into singlet oxygen. It is this very reactive singlet oxygen
which is thought to be the most important cytotoxic agent in
PDT, causing direct damage to many cellular sites like
plasma membrane, microsomes, mitochondria and nucleus as
well as to the microvasculature (Weishaupt et al., 1976; Star
et al., 1986; Henderson & Bellnier, 1989; Fingar et al., 1990).
The most common photosensitisers are haematoporphyrin
derivative (Hpd), a mixture of various porphyrins and
Photofrin®, a substance derived from Hpd and enriched in
the photodynamically active fraction (Lipson et al., 1961;
Dougherty et al., 1984; Kessel et al., 1987; Bonnet & Beren-
baum, 1989; Gomer et al., 1989).
Until now the application in liver tumours has been
restricted as liver tissue accumulates Photofrin more effici-
ently than the malignant tissue (Gomer & Dougherty, 1979;
Bugelski et al., 1981; Cozzani et al., 1984; Bellnier et al.,
1989). Therefore, superficial tumour illumination causes sub-
stantial liver necrosis (Pimstone et al., 1982). Moreover, the
limited light penetration during superficial illumination
makes it impossible to treat deep-seated or larger solid
tumours (Doiron et al., 1983). These limitations could be
overcome by implanting the light delivery fibres with diffus-
ing cylinder tips directly into the tumour (interstitial
therapy), thus applying the light selectively and with greater
accessibility (Dougherty et al., 1981; Holt et al., 1985;
Arnfield et al., 1986; 1989; Gatenby et al., 1987; Marijnissen
et al., 1992).
In the present study we therefore investigated the effects of
photodynamic therapy on tumour and surrounding normal
hepatic tissue using interstitial illuminations in a rat liver
metastasis model.
Materials and methods
Animals
One hundred and eight male Wag/Rij rats (Harlan CPB,
Austerlitz, The Netherlands), weighing 180-200g were used
for the experiments. They had free access to rat chow and
tap water. All animals received humane care, in accordance
with the guidelines for experimental animals of the Erasmus
University Rotterdam.
Tumour model
Colon adenocarcinoma CC531, a moderately differentiated
and syngeneic tumour transplantable to Wag/Rij rats, was
maintained subcutaneously (Marquet et al., 1984). Doubling
time was 2 weeks. On the day of inoculation the tumour was
excised from the donor rat, cut into pieces of approximately
2 mm3 and kept in Hank's balanced salt solution (HBBS).
Under ether anaesthesia a small midline laparotomy was
performed, followed by an incision in the left lateral lobe of
the liver. A piece of tumour was implanted and covered with
Lyostypt® (B. Braun Melsungen AG, Melsungen, Germany).
Laser illumination was performed 20 ± 1 days after tumour
inoculation. A relaparotomy was made under anaesthesia
with Hypnorm (Janssen Pharmaceutica B.V., Tilburg, The
Netherlands), mg kg-' body weight i.m., and the visible
diameter of the tumour was measured with sliding callipers.
Experimental design
The animals were randomly allocated to two experiments: I,
to assess short-term photodynamic effects and the biochemis-
try of liver damage; and II, to assess liver function and
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long-term effects, especially in relation to tumour remission.
In experiment I the animals were randomly assigned to
four groups: The experimental group (Photofrin and light,
n = 6 per light dose), a control group (laser light only, n = 6
per light dose), a control group (Photofrin only, n = 6) and a
control group (diffuser insertion only, n = 6). Two days
before laser illumination Photofrin was administered. On the
first and second day after laser treatment, blood was col-
lected for serum aspartate animotransferase (ASAT) and
alanine aminotransferase (ALAT) determination. On the
second day after laser, the animals were killed and the liver
was removed for histological determination of short-term
effects.
In experiment II the animals were randomly assigned to
two groups. The experimental group (n = 6 per light dose)
underwent the same treatment as in experiment I. The
animals in the control group (n = 6) received Photofrin with-
out any laser illumination. To determine liver function, an
antipyrine clearance test was performed on the first day after
laser treatment. All animals were killed on day 36 after laser
treatment for histological determination of long-term effects.
Photosensitiser
Photofrin (Quadra Logic Technologies Inc., Vancouver,
Canada and American Cyanamid, Lederle Laboratories,
Pearl River, USA) was administered in a dose of 5 mgkg-'
body weight by penile vein injection. After Photofrin
administration the animals were kept in subdued light, with
preservation of night-day rhythm, in order to avoid light-
induced skin damage as a result of Photofrin accumulation.
Light source
A Rhodamine B dye laser (Model 375B, Spectra Physics
Lasers, Mountain View, USA) pumped by an argon ion laser
(Model 171, Spectra Physics Lasers) was used to generate red
light of 625 ± 2 nm. This wavelength was chosen because
light of 625 nm wavelength appears to have a higher
biological effectivity than the conventionally used 630 nm
(Star et al., 1990). The dye-laser was tuned by a two-plate
birefringent filter using a monochromator. Light intensities
were monitored with a calibrated Optometer (Model 81,
United Detector Technology, Hawthorne, CA, USA), which
served as the reference.
Light delivery and dosimetry
The light was transmitted through a 200jam silicone cladded
flexible quartz fibre (Quartz and Silice, QSF-200) with a
custom-built cylindrical diffusing end of 0.5 cm length (Mari-
jnissen et al., 1985). The overall diameter of both the light
diffusing length and fibre itself was 600tim. The power emit-
ted by the diffuser was determined using an integrating
sphere (Model 2550, United Detector Technology) with a
radiometer (Optometer, model 181, United Detector Techno-
logy). A 19-guage needle was used to create an entry into the
centre of the tumour. To prevent adherence to the tissue,
some Vaseline was put on the diffuser. Following this, the
needle was withdrawn and the diffuser inserted using a stand
on which the fibre system was fixed (Figure 1). Laser illumin-
ation was then performed with energies (Joule cm' = watts
cm I x seconds of exposure) of either 100, 200, 400, 800 or
1600 J cm-' (length of cylindrical diffuser) at a power setting
of 200 mW cm-'. During illumination the liver was covered
with a black gauze soaked in saline solution to protect the
tissue from dehydration and to avoid influences from ambi-
ent light and laser light reflection. During treatment the
animals were kept on a heating plate to avoid cooling down
and rectal temperature was measured with a thermocouple
(Type C-RR2, Exacon). To give an indication of the actual
light dose delivered to the tissue, in a number ofexperiments
the light energy fluence (J cm-2, space irradiance) at the
tumour boundary was measured with a miniature isotropic
detector (Marijnissen et al., 1985; Marijnissen & Star, 1987).
Figure 1 Experimental set-up. The cylindrical diffuser of the
laser fibre is inserted into the tumour (L). The radiant energy
fluence at the tumour boundary is measured with a miniature
isotropic probe (F). Tissue temperature is measured with a ther-
mocouple system that is installed at the edge of the tumour (T).
Tumour temperature was determined with a needle thermo-
couple (Type C-N5, Exacon) connected to a read-out in-
strument (Model MC-9200, Exacon) that was positioned at
the edge of the tumour (Figure 1). The tumour periphery was
chosen for these measurements, as this would be the most
critical region for complete tumour cell destruction due to
the central diffuser position.
Determination ofphotodynamic effects
Histopathology After fixation in a 3.6% buffered formalin
solution for 5 days the livers were sliced through the plane of
the largest tumour diameter, embedded in paraffine and sec-
tioned at 5gm. Sections were mounted on glass slides and
stained with haematoxylin, azophloxin and saffron, for light-
microscopical examination.
Tissue damage On slides taken from animals killed on the
second day after PDT treatment the areas of hepatic necrosis
and vital or necrotic tumour were calculated by computer-
assisted integration of the circumference (IBAS 2000, Kont-
ron Bildanalyse GmbH, Munich, Germany). The maximal
width of the rim of hepatic necrosis was determined by IBAS
assisted measurements.
Tumour remission Tumour remission was assessed on the
basis of specimens taken from animals sacrificed 36 days
after PDT treatment. Complete tumour remission was con-
sidered when no tumour outgrowth (i.e. no vital tumour
tissue) could be observed by light microscopy. Additionally
the tumour area was measured by IBAS to give an indication
of tumour growth retardation.
Serum ASAT/ALAT To measure the amount of liver
damage the levels of serum ASAT and ALAT were deter-
mined in 0.5 ml blood on the first and second day after laser
treatment using standard laboratory equipment and techni-
ques at 30°C.
Antipyrine clearance test Liver function was determined by
antipyrine clearance on the first day after treatment. Anti-
pyrine in a dose of 100 mgkg-' body weight was admini-
stered by penile vein injection and blood samples of 0.5 ml
were collected by orbital puncture 1, 2 and 4 h after adminis-
tration. The plasma elimination half-life (T1/2) was then
determined from antipyrine levels measured by high-pressure
liquid chromatography according to Shargel et al. (1979).
All determinations were performed without knowledge of
treatment parameters.
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Figure 2 Histological overview of the tumour in the liver at different stages after PDT or sham treatment. (a) Vital tumour tissue in normal liver, 2 days after i.v. Photofrin only. (b) On the second day after PDT the tumour is largely necrotic, surrounded by a zone of necrotic liver tissue. (c) On day 36 the necrotic area has been replaced by connective scar tissue. This tumour shows complete remission. Bar: 1.7 mm (haematoxylin, azophloxin and saffron stain).1008 R. VAN HILLEGERSBERG et al.
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Figure 3 Histological sections of tumour tissue in the liver. (a) Tumour CC531 is a moderately differentiated adenocarcinoma. (b)
Tumour necrosis on the second day after PDT is characterised by disintegrated cells with acidophilic cytoplasm and pycnotic or fragmented nuclei. (c) Thirty-six days after treatment a granulomatous reaction with multinucleated giant cells is present. Bar:
50ltm (haematoxylin, azophloxin and saffron stain).PHOTODYNAMIC THERAPY OF LIVER METASTASES 1009
Statistical analysis
The values are expressed as means ± standard errors of the
mean (s.e.). Spearman's rank-order correlation was used to
analyse the relation between percentage of liver or tumour
necrosis, the ASAT, ALAT levels, the antipyrine elimination
half-life values and long-term tumour area on the energy
applied. The relation between liver necrosis and energy in the
control group treated with light energy only was tested after
dichotomisation, by the Mann-Whitney U test. The influence
of energy on tumour remission was determined by an Exact-
trend test. Other comparisons were made using the Student's
t test. A difference was considered to be significant at P
values of <0.05.
Results
In one animal the tumour implant did not grow; another
animal died during anaesthesia. All remaining animals sur-
vived and none of the animals showed signs of discomfort
after PDT treatment.
On the day of laser illumination the mean visible tumour
diameter of all animals (n = 106) was 5.7 ± 0.1 mm varying
from 4.0 to 8.0 mm.
Temperature andfluence
With 400 Jcm-' from the diffuser a fluence of 170 ± 30 J
cm 2 was measured at the boundary of 5.5 ± 0.5 mm dia-
meter tumour (n = 5). Slight changes in light penetration
through the tumour could be observed during PDT treat-
ment.
Baseline rectal temperature was 31.9 ± 0.4C (n = 18),
remaining constant during PDT treatment. The tumour core
temperature was 29.7 ± 0.6°C, varying from 27.5 to 34.3°C.
Generally the temperature at the tumour boundary increased
during illumination with a mean value of 3.3 ± 0.3°C, rang-
ing from 0.2 to 6°C. The absolute tissue temperature was
always less than 40°C. Tissue changes as previously observed
after thermal laser therapy, such as charring, cavitation or
elongation of cellular nuclei (Van Hillegersberg et al., 1991;
1992a) could not be identified in illuminated areas.
Histopathology
The general pattern of PDT induced tissue damage and
subsequent healing was unaffected by the variations in light
energy applied (Figure 2). Sections on the second day after
laser treatment showed massive tumour necrosis, charac-
terized by cellular debris and disintegrated cells with acido-
philic cytoplasm and pycnotic or fragmented nuclei (Figure
3a,b), surrounded by a polymorphonuclear inflammatory in-
filtrate (Figure 4). Depending on the amount of light energy
applied, islands ofvital tumour cells could be identified in the
necrotic tumour area (Figure 5). Around this area a zone of
liquefactive liver necrosis was visible which consisted of
dilated sinusoids and hepatocytes with vacuolated acidophilic
cytoplasm without nuclei (Figures 2b, 4). Remarkably, the
hepatic tissue had remained intact around the portal areas
(Figure 6). A second zone of inflammatory infiltrate sur-
rounded the hepatic necrosis.
Thirty-six days after PDT treatment two different situa-
tions could be observed:
(1) Complete tumour remission (Figure 2c); the necrotic area
was replaced by regenerated liver tissue and connective
scar tissue in which a granulomatous reaction with multi-
nucleated giant cells was present (Figure 3c).
(2) Tumour outgrowth, probably from the remaining islands
of vital tumour tissue.
Short-termphotodynamic effects
Tissue damage The mean (± s.e.) tumour diameter, derived
from areal measurements on short-term histological samples
(n = 71) was 5.8 ± 0.1 mm. Maximal width of the surround-
ing rim of liver necrosis varied from 2.6 ± 0.2 mm, after
100 J cm-' illumination to 3.7 ± 0.4 after 400 J cm-'.
The results of the measurements on the areas of hepatic
necrosis and vital or necrotic tumour are shown in Table I.
The total (i.e. vital + necrotic) tumour area ranged from
10.2 mm2 to 36.9 mm2 with a mean (± s.e.) value of 26.7 +
0.7 mm2 (n = 71). The mean (± s.e.) tumour necrosis varied
from 3.4 ± 0.6 mm2 after Photofrin administration only, to
23.6 ± 0.8 mm2 in the experimental group treated with 1600 J
cm-'. Mean (± s.e.) vital tumour area was 26.9 ± 1.7mm2 in
controls after Photofrin only, and 0.2 ± 0.1 mm2 after PDT
with 1600 J cm-'. Hepatic necrosis occurred in all experi-
mental groups, with a mean (± s.e.) maximal value of
Figure 4 Histological section on the second day after PDT. The necrotic tumours is surrounded by a zone of liquefactive liver
necrosis. The border between tumour and liver necrosis is infiltrated by inflammatory cells. Bar: 150ltm (haematoxylin, azophloxin
and saffron stain).1010 R. VAN HILLEGERSBERG et al.
Figure 5 Histological section on day 2 after PDT. An island of vital
(haematoxylin, azophloxin and saffron stain).
30.5 ± 1.4 mm2 after 1600 J cm-'.
As the amount of tumour necrosis is related to tumour
size, each measurement was expressed as percentage of the
individual total tumour area. For comparison, the same was
done for liver necrosis (Figure 7). Tumour necrosis was
found to increase with light energy delivered, with mean
values of 60.6 ± 6.6% at 100 J cmu' compared with 99.0 ±
0.6% at 1600 J cm-' (P<0.001). Liver necrosis was also
related to light energy, ranging from 87.8 ± 9.8% at 100 J
cm-' to 128.8 ± 8.3% at 1600 J cm-' (P = 0.001) (Figure 7a).
Control animals treated with Photofrin only, showed the
usual pre-existent central tumour necrosis, measuring 11.1 ±
1.7%. Diffuser insertion did not cause additional damage
(P = 0.09). However, after laser illumination only, a signi-
ficant relationship was found between tumour (P= 0.003) or
liver (P = 0.03) necrosis and energy delivered, with tumour
tumour cells in the necrotic tumour area. Bar: 50jLm
necrosis of 35.7 ± 9.8% at 800 Jcmu' and 54.0 ± 12.3% at
1600 J cm-', accompanied by liver necrosis of 1.4 ± 0.9%
and 5.0 ± 3.5% respectively (Figure 7b). Tumour necrosis in
this group was limited to the central area around the diffuser
and had a similar appearance as the earlier described photo-
dynamic damage. Liver necrosis occurred only at the dorsal
tumour border, where the diffuser probably had penetrated
hepatic tissue.
Serum ASAT/ALAT Serum ASAT and ALAT levels on the
first day after treatment were increased in the experimental
group and the control group treated with light only (Figure
8a,b). The values were related to the amount of light energy
applied (P<0.001). After a plateau at 1OOJcmur, however,
a strong increase was found at energies over 400 J cm -. No
difference was found between ALAT levels of control
Figure 6 Histological section on day 2 after PDT. Liver tissue around the portal areas has remained intact. Bar: 150gtm
(haematoxylin, azophloxin and saffron stain).PHOTODYNAMIC THERAPY OF LIVER METASTASES 1011
Table I Mean (±s.e.) area ofhepatic necrosis, tumour necrosis and
vital tumour tissue on the second day after PDT' (in mm2)
No. of Tumour Tumour Liver
Energy (Jcm-') animals vital necrosis necrosis
Control groupsb
Photofrin 6 26.9± 1.7 3.4±0.6 -
Diffuser 6 27.3± 1.5 4.8±0.5 -
100 6 22.9±0.8 5.8±0.7 -
200 6 22.6± 1.6 4.9±0.7 -
400 6 18.7±2.7 5.1±1.2 -
800 6 18.1±3.7 8.7±1.8 0.4±0.3
1600 6 12.3±2.9 15.8±3.9 1.3± 1.0
Experimental groups
100 6 10.2± 1.7 16.2±2.5 22.2± 1.8
200 6 3.6±1.5 23.1±2.2 25.3±1.1
400 6 2.5± 1.0 20.0± 1.4 25.8±6.0
800 5 0.3±0.1 23.2±2.0 28.0±2.9
1600 6 0.2±0.1 23.6±0.8 30.5± 1.4
aLaser illumination with 200 mWcm-' was performed 2 days after
Photofrin administration (5 mgkg-' i.v.). bControl animals received
eitherPhotofrin only, diffuserinsertiononly, orlaserillumination only.
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Figure 8 (a) Serum ALAT and (b) ASAT level vs energy
delivered in the experimental group (0) and control group
treated with laser light only (0) on the first day after laser
treatment. Animals treated with Photofrin only served as cont-
rols. Each point represents the mean (±s.e.) of six experimental
results.
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Figure 7 Tumour and liver necrosis as percentage of the individ-
ual total tumour area vs energy delivery on the second day after
laser treatment in (a) the experimental and (b) control group
treated with laser light only. Each point represents the mean
(±s.e.) of at least five experimental results. Control animals
treated with Photofrin only, served as starting point at energy
level 0. The dashed line describes the total tumour area.
animals treated with Photofrin only compared with diffuser
insertion only (P = 0.9). ASAT levels, however, showed a
significant difference, with values of 42.4 ± 3.1 IU 1' after
Photofrin only compared with 62.4 ± 7.7 IU 1-1 after diffuser
insertion (P = 0.01).
On the second day after treatment enzyme levels were still
slightly increased with maximum values in the experimental
group of 71.7 ± 3.9 IU 1' for ALAT and 119.7 ± 7.5 IU 1'
for ASAT at 1600 J cm- '.
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tion were not related to energy applied (P = 0.29) (Table II).
-------------------------------- _Long-term effect on tumour remission
All tumours in control animals showed massive outgrowth
with infiltration to adjacent tissue. In the experimental group
several animals showed complete tumour remission. Best
results were obtained at 800Jcm-' with complete remission
in 4 out of 6 animals (Table III). Owing to the unfavourable
results at 1600 J cm'1
- merely 1 out of 6 tumours in com-
plete remission
- no significant relation was found between
number of tumours in remission and light energy delivered
(P = 0.08). The size of the tumour area on day 36 after PDT
(Table III) was related to the amount of light energy
delivered (P<0.001) as would be expected from the results
on the second day after treatment (Figure 7a).
Discussion
In this study the ability of interstitial photodynamic therapy
to cause major destruction of solid tumours within the liver
was demonstrated. Histological examination showed tumour
cell necrosis 2 days after PDT treatment and connective scar
tissue on day 36. Interstitial treatment enabled selective
illumination of the tumour combined with deep tissue penet-
ration, resulting in compelte tumour remission in 4 out of 6
cases at 800Jcm-' (diffuser length). Despite local illumina-
tion, surrounding liver damage occurred at all energies app-
lied. However, liver necrosis was limited to a distinct zone of
2-4 mm width and did not deteriorate liver function as
measured by antipyrine clearance.
In previous studies several attempts have been made to
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TableII Mean(±s.e.)antipyrineplasmaeliminationhalf-lifelevelson
the first day after laser treatmenta
Energy (Jcm-') No. ofanimals T 1/2 (h)
Controlb 5 2.0±0.1
100 4 2.0±0.1
200 6 1.9±0.0
400 6 1.9±0.1
800 6 2.1±0.1
1600 6 2.0±0.1
aLaser illumination with 200 mWcm-' was performed 2 days after
Photofrin administration (5 mgkg-' i.v.). bControl animals received
Photofrin only.
Table III Remission and vital tumour area on the 36th day after laser
treatmenta
Energy (Jcm-') No. oftumours in Mean (±s.e.) Tumour
complete remissionb area (mm2)
Controlc 0/6 209±21
100 0/5 180±54
200 2/6 77± 34
400 2/6 13±6
800 4/6 7± 5
1600 1/6 64±20
aLaser illumination with 200 mWcm' was performed 2 days after
Photofrin administration (5 mgkg-' i.v.). bNo. oftumours in complete
remission/no. ofanimals. CControl animals received Photofrin without
any laser illumination.
solve the problem of efficient photosensitiser accumulation in
the liver. Kita et al. (1987) found that indocyanine green
after i.v injection, protects photosensitised hepatocytes
against illumination with green light. Nishiwaka et al. (1989)
used intra-arterial administration of the photosensitiser.
Pheophorbide to cause selective accumulation in liver
tumours. Interstitial therapy, however, can be applied in
combination with Photofrin, the only clinically used photo-
sensitiser, and additionally provides the possibility of treating
deep-seated solid tumours.
There are no data available on Photofrin distribution of
intrahepatic tumour and surrounding liver at different time
intervals after administration. We therefore based the interval
between Photofrin administration and illumination on pre-
vious studies in experimental animals carrying extrahepatic
tumours. These studies showed an optimal porphyrin concen-
tration ratio between tumour and liver after a period of 2
days (Gomer & Dougherty, 1979; Cozzani et al., 1984; Jori et
al., 1986).
An increase in light dose delivered, resulted in a higher
percentage of tumour necrosis in the experimental group,
with maximum values of 99.0 ± 0.6% at 1600 J cm-' (Figure
7a). Remarkably, tumour necrosis also appeared in control
animals treated with laser light only (Figure 7b). Bown et al.
(1986) have studied the effects of different power outputs on
PDT in normal rat liver. They found that 400 mW red light
from an interstitial bare tipped fibre significantly heated the
tissue, resulting in charring at the fibre tip within 1 min. The
light transmission in the tissue dropped accordingly to under
10%. At 100 mW power output, however, light transmission
remained constant and no thermal tissue changes were found.
In the present study we used the same power output of
100 mW, from a 0.5 cm cylindrical diffuser (i.e. 200 mW
cm-'). By using a diffuser, the light is emitted from a larger
surface area resulting in a more uniform light delivery. Thus
the heat generated in this manner is much less localised and
intense than with a bare fibre tip. Indeed, charring could not
be observed on histological specimen and temperature at the
tumour boundary was always less than 40C. However, as
tumour necrosis in the control group treated with light only
was limited to the area around the diffuser, higher tempera-
tures might have occurred there resulting in hyperthermic
effects at longer exposures. Another explanation, however,
might be the activation of pre-existent endogenous por-
phyrins (Van Hillegersberg et al., 1992b).
Although PDT has been shown to be synergistic with
hyperthermia (Waldow & Dougherty, 1984; Waldow et al.,
1987; Matsumoto et al., 1990), thermal influences are nor-
mally avoided in fundamental studies to investigate exclus-
ively the PDT effect. A power output of 200 mWcm' was
therefore applied in this study. However, as PDT damage
depends largely on the total energy delivered (Joules =
Watts x seconds), the exposure time has to be corresponding-
ly longer at lower dose rates. We used a maximal exposure
time of 2 h and 13 min (1600 Jcm-') in this study. In clinical
PDT, however, higher power outputs may be applied (as
long as charring is avoided) to keep exposure time within
boundaries. For example 400mW cm-, delivered intersti-
tially during 8-12min (200-300 Jcm-') is a standard treat-
ment for patients with endobronchial tumours (Balchum &
Doiron, 1985).
Tumour growth retardation, as measured by the tumour
area on the 36th day after PDT, was related to the amount
of light energy delivered as would be expected from the
amount of tumour necrosis on the second day after treat-
ment. Up to 800 Jcm-', a similar relation was found for the
number of tumours in complete remission. The unfavourable
results at 1600 J cm-1, however, led to an overall non-
significant relation between tumour remission and energy
applied, suggesting an optimum relation between light dose
and tumour response (Table III). From the current know-
ledge of the photodynamic reaction, however, these results
can hardly be explained. Singlet oxygen, the most important
cytotoxic agent in PDT, is generated via the so-called Type II
mechanism of photosensitised oxidation (Weishaupt et al.,
1976; Keene et al., 1986; Foote, 1991). Upon absorption of a
photon, the porphyrin molecule is brought to an excited
singlet state that undergoes intersystem crossover to the
excited triplet state. Transfer of energy from the triplet
photosensitiser to available oxygen creates the reactive singlet
oxygen. The electrophilic nature of singlet oxygen makes it
very efficient at producing oxidised forms of biomolecules
(Gomer, 1989). Thus, the photocytotoxic reaction occurs
exclusively during illumination, which makes it unlikely that
doubling the light dose (i.e. from 800 J cm-' to 1600 Jcm-')
would reduce the photodynamic effect.
The appearance of nests of apparently therapy resistant
tumour cells in the necrotic area after PDT has previously
been described by Pimstone et al. (1982) and Holt et al.
(1985) in rat hepatoma. There could be several mechanisms
underlying this phenomenon, assuming the heterogeneity of
tumour tissue:
(1) The incorporation of Photofrin in these cells is disturbed
as a result ofpoor vascular supply or altered transmemb-
rane passage which may cause low levels of photosen-
sitiser.
(2) The cells are in a dormant state with very low 02
metabolism and no singlet oxygen production.
(3) Vessels with a diameter larger than 1.3 mm produce a
cytoprotective shadowing effect, thus preventing appro-
priate illumination of the cells (Pimstone et al., 1982).
(4) The total light dose is too low to achieve photodynamic
destruction in all tumour cells.
Kato et al. found an uneven distribution of Photofrin
fluorescence in early stage bronchus carcinoma, which could
be evidence for state (1) (H. Kato, personal communication,
1991). The nests of vital tumour cells were randomly spread
over the necrotic tumour area and a clear relation to vascular
structures could only be identified twice (statement 3). Liver
damage, however, was strongly related to the liver anatomy
as hepatic cells survived around the portal areas (Figure 6).
This phenomenon is probably due to a different hepatocyte
environment (perfusion, and hence supply of nutrients) and
enzyme content in the periportal compared with pericentral
domains (Lamers et al., 1989). Thus, substances such as
unsaturated fatty acids, that act as oxygen scavengers, and
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mutases would prevent oxidative damage in the periportal
areas (Jungermann & Katz, 1989; Byczkowski & Gessner,
1988; Gutteridge & Halliwell, 1990). Knowledge about the
mechanism responsible for the survival of specific tumour
cells could lead to treatment strategies causing complete
tumour destruction. When for instance a low concentration
of Photofrin is caused by efficient transmembrane transport
of porphyrins out of the cells, Ca2+ blocking agents could be
a solution. Photofrin delivery to intrahepatic tumours might
be improved by increasing tumour capillary flow with appro-
priate vasoactive agents (Ackerman et al., 1988). The mech-
anism responsible for porphyrin accumulation in tumours is
still unclear. In a recent study, however, we showed that a
decreased conversion to haem, owing to decreased ferroche-
latase activity may be an important factor (Van Hillegersberg
et al., 1992b). Dailey & Smith (1984) have shown that several
representative porphyrins in Photofrin are substrates for
ferrochelatase. Therefore, modulation of this enzyme could
be another approach (Smith, 1987).
As the diffuser was inserted into the centre of the tumour,
higher light doses were applied to the tumour than to the
surrounding liver tissue. However, on the second day after
treatment at all energies a rim of liver necrosis was visible
around the tumour, whereas at lower energies tumour tissue
had remained largely intact. This could be the result of the
unfavourable porphyrin concentration ratio between liver
and tumour, which was found to be 3:1 after i.v. Photofrin in
this model (Van Hillegersberg et al., 1992b).
In this study liver necrosis increased with energy delivered,
but a plateau occurred beyond 400 J cm-', indicating that
higher laser energies could be applied without much more
liver damage. An important factor in this matter is the
difference in optical properties between the dark red coloured
liver and the whitish tumour (Van Hillegersberg et al.,
1992c). The hepatic tissue effectively absorbs 625 nm light,
which limits the light penetration in liver, and by that limits
liver damage. This difference in absorption coefficient might
be beneficial in the clinical application, where the peripheral
interstitial diffuser would produce a comparable amount of
liver damage.
Serum ASAT and ALAT levels on the first and second day
after treatment were used as biochemical parameters for liver
damage. Indeed a significant relation between enzyme level
and delivered light energy was found, confirming our
measurements on the area of hepatic necrosis in the experi-
mental group. However, the rise in ASAT level after diffuser
insertion only, did not correspond to the normal histological
appearance of surrounding liver tissue. Recently we measured
ASAT and ALAT concentrations in rat liver and tumour
CC531. The ALAT concentration ratio between tumour and
liver was found to be 1:40, whereas ASAT ratio was 1:2,
indicating that the serum ALAT level is the most appropriate
parameter for liver damage in this model (unpublished data).
Thus the increase in serum ASAT after diffuser insertion is
probably due to tumour, rather than liver damage. A similar
explanation could be applied to the rise in ASAT level after
treatment with light only, especially at energies (400J
cm '. In this group liver necrosis appeared at 800 and
1600 J cm-1, resulting in a higher ALAT level (Figures 7 and
8).
In this study we used a single PDT treatment with a fixed
diffuser position to determine the photodynamic effects as
standardised as possible. We therefore chose a tumour model
in the rat, where the mean diameter of the tumour at time of
treatment was approximately 6 mm so that the effects on the
tumour and on the adjacent liver tissue could be determined.
Larger tumours, however, could be treated by multiple
diffuser implantation (Marijnissen et al., 1992). In this respect,
fluence measurements at the tumour boundary would give
important information to compare with the light dose
delivered in this study (i.e. 170 ± 30 Jcm2 with 400 J cm-I
from the diffuser). As the diffuser can be passed down a
needle under ultrasound guiding, percutaneous treatment of
several tumours at different liver lobes would be possible
(Gatenby et al., 1987). This local treatment of tumour can
substantially reduce the surgical trauma and may as such
diminish complications like bleeding and liver failure.
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